Hikal reports Q1 FY26 consolidated loss of Rs. 22.4 Cr
Hikal has reported total income of Rs. 381.4 crores during the period ended June 30, 2025
Hikal has reported total income of Rs. 381.4 crores during the period ended June 30, 2025
This is the group’s first NoC approval in Canada
Vasograin Plus represents a major advancement in the treatment of migraine
The expansion will bring together talent in AI, data science, and engineering to build the digital foundation needed to accelerate drug discovery and delivery
The company reported a 28% year-on-year increase in Q2 revenue to Rs. 220.9 crore
The facility includes advanced laboratories to monitor market trends, consumer needs, product innovation, and formulation improvements
Mehta brings strong leadership experience in biopharmaceuticals, life science research, and diagnostics
He most recently served as Chief Medical Officer of AstraZeneca and Alexion
Subscribe To Our Newsletter & Stay Updated